Under the collaboration, Ablynx will provide access to novel Nanobodies, generated using proprietary technology platform, and Algeta will provide access to chelation and conjugation technologies, as well as
As part of the agreement, in early 2013 LifeMap Sciences will provide more than a 1000 recombinant proteins and antibodies, many of them related to stem cell research.
ATIR Phase II study is a confirmatory multi-center, proof-of-concept study. Kiadis Pharma CEO Manfred Ruediger said the support from existing and new investors attests to the clinical data
The cyclophilin inhibitors drugs include CicloMulsion and NeuroSTAT which are intended to treat heart reperfusion injury after stenting and traumatic brain injury respectively. Both the products prevent the
As part of the agreement, Canadian urologists will be able to order PCMT through CML HealthCare in early 2013. PCMT by applying mitochondrial DNA analysis to tissue samples
The study compared the difference in opioid use, total hospital cost and length of stay (LOS) between patients receiving Exparel as the base of an opioid-sparing multimodal regimen
The sublingual once daily medication should be administered from four months prior to the onset of season and continued all through the seasonal period. Paladin Labs interim president
The drug candidate is being studied to treat acquired hemophilia A individuals who developed inhibitory antibodies in opposition to their inborn FVIII. Inspiration considers submitting a biologics license
The CPGR will leverage Affymetrix GeneTitan multi-channel (MC) instrument to offer gene expression and Axiom genotyping services to researchers in the region. CPGR Managing Director Dr Reinhard Hiller
Eliquis 5mg, trade name of apixaban in Europe, is indicated as a twice-daily drug for preventing strokes and systemic embolism in nonvalvular atrial fibrillation (NVAF) adult patients. Oral
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.